Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Genesis Pharma Completes 40-to-1 Reverse Split

publication date: Sep 4, 2008

Genesis Pharmaceuticals Enterprises has effected a 40-to-1 reverse stock split and changed its ticker symbol to GNPH from the previous symbol GTEC. As before, Genesis Pharma trades on the OTC Bulletin Board Exchange. After the reverse split, Genesis has 10.3 million shares outstanding. Cao Wubo, Chairman and CEO of Genesis, said in a statement that the reverse split was part of a strategic initiative to move its listing to a “senior” stock exchange in the US. More details...

Stock Symbol: (OTCBB: GNPH)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital